TOKYO, JAPAN – October 02, 2023 – Terumo Corporation (TSE: 4543) today announced that it has agreed with U.S.-based Dexcom, Inc (Dexcom) to cease the distribution agreement for Dexcom's Continuous Glucose Monitoring Systems (CGM) in Japan, as of March 31, 2024. This decision was made in accordance with Dexcom's change in marketing strategy to shift from indirect distribution to direct sales in certain key markets, excluding the U.S.
With this arrangement, Terumo will cease the sales and support activities for Dexcom's CGM in Japan on March 31, 2024. These activities will be performed directly by Dexcom from April 2024. Terumo and Dexcom are both committed to maintaining an excellent level of service and support for patients with diabetes and their healthcare providers throughout this transition.
For more than 40 years, Terumo has developed and launched a range of medical devices designed to enhance QOL of people with diabetes. This includes the world’s shortest and thinnest* insulin injection needle “NANOPASS” and the first insulin patch pump available in Japan “MEDISAFE WITH”.
Terumo positions the business related to diabetes as one of the key pillars of its growth strategy. To fulfill the company’s commitment to improving the QOL of people with diabetes, Terumo will continue to deliver products including SMBG devices, insulin injection needles and insulin patch pumps to the market, while accelerating the development of Automated Insulin Delivery (AID) System and other new solutions.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.